Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ZJAMP Group Co., Ltd. is a Chinese pharmaceutical company specializing in the development and manufacturing of generic and specialty drugs. Its competitive position is bolstered by a robust portfolio of over 100 products, primarily in the cardiovascular and anti-infective segments, and a significant presence in both domestic and international markets.
ZJAMP generates revenue primarily through the sale of generic and specialty pharmaceuticals, leveraging its extensive distribution network across China and expanding into international markets. The company benefits from economies of scale in production, allowing for competitive pricing and improved margins.
Approval of new drug applications in China and abroad
Changes in regulatory policies affecting generic drug pricing
Market share gains in key therapeutic areas
Fluctuations in raw material costs impacting margins
Regulatory changes in drug approval processes
Technological disruption in drug manufacturing
Intense competition from domestic and international generic manufacturers
Potential entry of new players in specialty pharmaceuticals
High debt levels relative to equity may constrain financial flexibility
Liquidity risks due to reliance on cash flow generation
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Interest rates can impact ZJAMP's financing costs, particularly given its debt/equity ratio of 1.97, which may affect its ability to invest in growth initiatives.
minimal - The company does not heavily rely on credit markets for its operations.
value - The low Price/Sales ratio of 0.1x and Price/Book ratio of 0.7x may attract value-focused investors seeking undervalued opportunities.
high - The stock has demonstrated significant volatility, with a 3-month return of -27.5%.